# OnCo record nct04725331 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04725331/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04725331", "NCT04725331" ;
  schema:name "A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of BT-001 run by Transgene, terminated."@en ;
  schema:url <https://onco.cc/trials/nct04725331/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04725331> ;
  onco:status "historic" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/bt-001/> ;
  onco:companies <https://onco.cc/companies/bioinvent-international/>, <https://onco.cc/companies/transgene/> .